Novartis News | finanzen.ch

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

01.10.13	Pharmaceutical Companies Announce Trial Results, and Achieve New Contracts, Regulatory Approvals, and Positive Opinion - Research Report on Eli Lilly, Pfizer, Novartis, Sanofi, and AstraZeneca (PR Newswire)
01.10.13	Roche-Chef geht auf Grossaktionär Novartis zu - Offen für Gespräche (dpa-afx)
30.09.13	Presentation, Licensing Agreement, Trial Milestone, Positive Opinion, and Trade Name Acceptance - Research Report on Pfizer, Allergan, Novartis, AstraZeneca, and Rockwell Medical (PR Newswire)
30.09.13	Novartis To Reveal Phase III Results From Dermatology Portfolio - Quick Facts (RTTNews)
27.09.13	Novartis: Lucentis Data Confirms Transformational Efficacy, Safety Profile (RTTNews)
27.09.13	Press Release: New data for Novartis drug -2- (Dow Jones)
27.09.13	Press Release: New data for Novartis drug Lucentis(R) reinforces transformational efficacy and well-established safety profile across four indications (Dow Jones)
25.09.13	Pre-Market Review: Dendreon Corp., Stryker Corp., Novartis AG, and Repros Therapeutics Inc. (PR Newswire)
25.09.13	Press Release: Data at ECTRIMS to confirm -2- (Dow Jones)
25.09.13	Press Release: Data at ECTRIMS to confirm Novartis' Gilenya(R) long-term efficacy on reducing brain volume loss and real-world relapse rates in MS (Dow Jones)
25.09.13	Novartis Confirms Long Term Benefits Of Gilenya In Multiple Sclerosis (RTTNews)
23.09.13	Novartis To Support Power Of One Campaign - Quick Facts (RTTNews)
23.09.13	Thomson Reuters ONE/Malaria No More und Novartis starten "Power of One", eine weltweite digitale Spendenkampagne, die zur Ausmerzung von Malaria bedingten... (Dow Jones)
23.09.13	Thomson Reuters ONE/Malaria No More et Novartis lancent Power of One, une campagne numérique mondiale de collecte de fonds visant à contribuer à l'élimina... (Dow Jones)
23.09.13	Press Release: Malaria No More and Novartis launch Power of One, a global digital fundraising campaign to help eliminate malaria deaths (Dow Jones)
23.09.13	Press Release: Novartis first-in-class once-daily -3- (Dow Jones)
23.09.13	Press Release: Novartis first-in-class once-daily -2- (Dow Jones)
23.09.13	Press Release: Novartis first-in-class once-daily dual bronchodilator Ultibro Breezhaler (QVA149) achieves near simultaneous approval for COPD patients in Eu... (Dow Jones)
23.09.13	Novartis' QVA149 Gains EC Approval For COPD Patients In Europe & Japan (RTTNews)
19.09.13	Press Release: Novartis marks World CML Day with -3- (Dow Jones)
19.09.13	Press Release: Novartis marks World CML Day with -2- (Dow Jones)
19.09.13	Press Release: Novartis marks World CML Day with update on global research program to evaluate whether Ph+ CML patients can live treatment-free (Dow Jones)
19.09.13	Novartis Updates On Global Research Program - Quick Facts (RTTNews)
18.09.13	Clinical Trial Results, Licensing Agreements, Breakthrough Research and Development Programs - Research Report on Pfizer, Merck, Rockwell Medical, GlaxoSmithKline, and Novartis (PR Newswire)
17.09.13	Critical Alerts For First Solar, Novartis, Boston Beer Company, SAP, and Dish Network Released By InvestorsObserver (PR Newswire)
17.09.13	Clinical Trial Updates, Appointments, FDA Acknowledgments and Qualifications - Research Report on Novartis, Endo, The Medicines Company, United Therapeutics, and Forest (PR Newswire)
17.09.13	Sanofi erhält für Multiple Sklerose-Medikament Lemtrada Zulassung in Europa (dpa-afx)
10.09.13	FDA and EMA Submissions, Partnerships, Milestones, Participation Withdrawals, and Prequalifications - Research Report on Johnson & Johnson, Novartis, AstraZeneca, Astex Pharmaceuticals, and Sanofi (PR Newswire)
09.09.13	Novartis Says Data From Ultibro Breezhaler Studies For COPD Shows Improvement (RTTNews)
08.09.13	PRESS RELEASE: Novartis data presented at ERS -3- (Dow Jones)
08.09.13	PRESS RELEASE: Novartis data presented at ERS -2- (Dow Jones)
08.09.13	PRESS RELEASE: Novartis data presented at ERS showcases once-daily COPD portfolio and further demonstrates efficacy of Ultibro(R) Breezhaler(R) (QVA149) (Dow Jones)
06.09.13	PRESS RELEASE: Novartis announces an exclusive global licensing and research collaboration with Regenerex, leveraging a novel cell platform to broaden presen... (Dow Jones)
06.09.13	Novartis, Regenerex Ink Licensing, Research Collaboration - Quick Facts (RTTNews)
04.09.13	PRESS RELEASE: Novartis showcases 39 abstracts -4- (Dow Jones)
04.09.13	PRESS RELEASE: Novartis showcases 39 abstracts -3- (Dow Jones)
04.09.13	PRESS RELEASE: Novartis showcases 39 abstracts -2- (Dow Jones)
04.09.13	PRESS RELEASE: Novartis showcases 39 abstracts highlighting robust respiratory portfolio at ERS 2013 (Dow Jones)
04.09.13	PRESS RELEASE: Novartis marks 30 year anniversary -2- (Dow Jones)
04.09.13	PRESS RELEASE: Novartis marks 30 year anniversary in transplantation and reinforces continued commitment to organ recipients at ESOT congress (Dow Jones)
03.09.13	Novartis' Ilaris Gets EU Approval For Juvenile Idiopathic Arthritis - Update (RTTNews)
03.09.13	PRESS RELEASE: Novartis receives EU approval for -2- (Dow Jones)
03.09.13	PRESS RELEASE: Novartis receives EU approval for Ilaris(R) in active Systemic Juvenile Idiopathic Arthritis, a serious form of childhood arthritis (Dow Jones)
03.09.13	Novartis Gets EU Approval For Ilaris In Systemic Juvenile Idiopathic Arthritis (RTTNews)
02.09.13	Novartis: RLX030 Found Effective Across Multiple Subgroups Of Heart Patients (RTTNews)
02.09.13	PRESS RELEASE: Novartis' serelaxin (RLX030) -2- (Dow Jones)
02.09.13	PRESS RELEASE: Novartis' serelaxin (RLX030) improved symptoms and mortality across multiple subgroups of patients with acute heart failure[1],[2] (Dow Jones)
02.09.13	Novartis: RLX030 Improved Symptoms, Mortality In Heart Patients (RTTNews)
02.09.13	Acquisitions, Topline Results, New Board Members, Events, and Product Milestones - Research Report on Johnson & Johnson, Sanofi, Lilly, AbbVie, and Novartis (PR Newswire)
27.08.13	ROUNDUP 2: Streit um Umfüllung von Augenmittel - Novartis muss Antrag ändern (dpa-afx)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Logitech Intl	71.60	2.20 %	K V
Part Grp Hldg	1’274.50	1.63 %	K V
Lonza Grp	523.20	1.20 %	K V
UBS Group	28.00	1.19 %	K V
Sika	229.10	1.10 %	K V
Sonova Hldg	305.20	0.39 %	K V
Nestle	76.66	0.39 %	K V
Zurich Insur Gr	554.00	0.25 %	K V
Givaudan	3’870.00	-0.26 %	K V
CieFinRichemont	121.55	-0.29 %	K V

mehr

12.07.24		Novartis- und MorphoSys-Aktien gewinnen: Novartis kurbelt Squeeze-Out bei MorphoSys an
12.03.24		MorphoSys- und Novartis-Aktien uneinig: Bundeskartellamt erlaubt MorphoSys-Übernahme durch Novartis
31.01.24		Novartis-Aktie schwach: Novartis profitiert von Sandoz-Abspaltung - Gewinnsprung
12.06.23		Novartis-Aktie im Plus: Novartis legt für Chinook Milliardensumme auf den Tisch
25.04.23		Novartis-Aktie im Plus: Novartis hebt nach gutem Jahresbeginn die Umsatzprognose an
07.12.22		MorphoSys-Aktie und Novartis-Aktie gefragt: Krebsprogramm gegen Zahlung an Novartis auslizenziert
19.07.22		Novartis-Aktie höher: Novartis bei nahezu stabilen Umsätzen mit Gewinnrückgang - Umbau soll 1,5 Milliarden US-Dollar Kosten sparen
06.05.22		Novartis-Aktie im Minus: Produktion von Krebsmitteln in Italien und USA ausgesetzt